

Patent Application
Attorney Docket No. PC10743A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Alan, et al. :

APPLICATION NO.: 09/884,211 : Examiner: Not Yet Assigned

FILING DATE: June 18, 2001 : Group Art Unit: Not Yet Assigned

TITLE: NOVEL MELANOCORTIN-4 :
RECEPTOR SEQUENCES AND
SCREENING ASSAYS TO IDENTIFY
COMPOUNDS USEFUL IN
REGULATING ANIMAL APPETITE
AND METABOLIC RATE

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

Patent Application
Attorney Docket No. PC10743A

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: October 29, 2001

Lorraine B. Ling
Lorraine B. Ling
Attorney for Applicant(s)
Reg. No. 35,251

Pfizer Inc
Patent Department
150 East 42nd Street - 105/5/49
New York, NY 10017-5612
(212) 573-2030

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC10743A			SERIAL NO. 09/884,211		
									APPLICANT Alan, et al.					
									FILING DATE June 18, 2001			GROUP 1623		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4	3	7	6	1	1	0	03/08/83	David, et al.					
	4	8	7	3	1	9	1	10/10/89	Wager, et al.					
	4	9	4	6	7	7	8	08/07/90	Ladner, et al.					
	5	6	2	2	8	6	0	04/22/97	Yamada, et al.					
	5	7	0	3	2	2	0	12/30/97	Yamada, et al.					
	5	8	6	9	2	5	7	02/09/99	Yamada, et al.					
	5	9	3	2	7	7	9	08/03/99	Lee, et al.					
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
	8	9	1	0	1	3	4	11/02/89	PCT					X
	9	0	1	1	3	6	4	10/01/90	PCT					X
	9	2	2	0	7	0	2	11/26/92	PCT					X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
1.	Bray, et al.; Neuroendocrine Control of the Development of Obesity: Understanding gained from studies of experimental animal models; <i>Frontiers in Neuroendocrinology</i> ; (1990) Vol. 11 No. 2 pp. 128-181.													
2.	Flier, et al.; Obesity and the Hypothalamus: Novel peptides for new pathways; (1998) <i>Cell</i> , 92:437-440.													
3.	Gispén, et al.; Brain Melanocortin Receptors: from cloning to function; <i>Peptides</i> ; (1997) Vol. 18, No. 8, pp. 1287-1997.													
4.	Mountjoy, et al.; The cloning of a family of genes that encode the melanocortin receptors; (1992) Vol. 257: 1248-1251.													
5.	Chhajlani, et al.; Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA; <i>FEBS Let.</i> , (1992) 309:417-420.													
6.	Roselli-Rehfuß, et al.; Identification of receptor for γ melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system; <i>Proc. Natl. Acad. Sci.</i> (1993) Vol. 90, pp. 8856-8860.													
7.	Gantz, et al.; Molecular cloning of a novel melanocortin receptor; <i>The J. of Biological Chem.</i> ; (1993) Vol. 268:8246-8250.													
8.	Mountjoy, et al.; Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain; <i>Mol. Endocrinology</i> ; 8:1298-1308.													
9.	Chhajlani, et al.; Molecular cloning of a novel human melanocortin receptor; <i>Biochem. Biophys. Res. Commun.</i> 195:866-873.													

Express Mail No. EL768261670US

10.		Gantz, et al.; Molecular cloning, expression, and characterization of a fifth melanocortin receptor; (1994) Biochem. Biophys. Res. Commun. Vol. 200, No. 3, pp 1214-1220.
11.		Hruby, et al.; Cyclic lactam α -melanotropin analogues of Ac-Nle ⁴ -cyclo[Asp ⁵ ,D-Phe ⁷ , lys ¹⁰]- α -melanocyte-stimulating hormone-(4-10)-NH ₂ with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors; J. Med. Chem.; (1995) 38:3454-3461.
12.		Adan, et al.; Identification of antagonists for melanocortin MC ₃ , MC ₄ and MC ₅ receptors; Eur. J. Pharmacol. (1994) 269:331-337.
13.		Alvaro, et al.; Morphine Down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction; Molecular Pharmacology; (1996) 50:583-591.
14.		Fan, et al.; Role of melanocortinergic neurons in feeding and the agouti obesity syndrome; Nature; (1997) 385:165-168.
15.		Moussa, et al.; The yellow mouse obesity syndrome and mechanisms of agouti-induced obesity; Obesity Research; (1999) Vol. 7 No. 5 pp. 506-514.
16.		Fisher, et al.; Melanocortin-4 receptor: A novel signalling pathway involved in body weight regulation; Intern. J. of Obesity; (1999) 23 Suppl. 1:54-58.
17.		Lu, et al.; Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor; Nature; (1994) Vol. 371 799-802.
18.		Huszar, et al.; Targeted disruption of the melanocortin-4 receptor results in obesity in mice; Cell; (1997) Vol. 88, pp 131-141.
19.		Marsh, et al.; Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides; Nature; (1999) pp. 199-222.
20.		Kask, et al.; Evidence of involvement of the melanocortin MC ₄ receptor in the effects of leptin on food intake and body weight; European J. of Pharmacology; (1998) 360:15-19.
21.		Harrold, et al.; Altered energy balance causes selective changes in Melanocortin-4 (MC4-R), but not melanocortin-3 (MC3-R), receptors in specific hypothalamic regions; Diabetes (1999) 48:267-271.
22.		Harrold, et al.; Changes in hypothalamic agouti-related protein (AGRP) but not α -MSH or pro-opiomelanocortin concentrations in dietary-obese and food-restricted rats; Biochemical Biophys. Res. Commun. (1999) 258:574-577.
23.		Bednarek, et al.; Analogs of MTII, lactam derivatives of α -melanotropin, modified at the n-terminus, and their selectivity at human melanocortin receptors 3, 4 and 5; Biochemical Biophys. Res. Commun. (1999) 261:209-213.
24.		Canuthers, et al.; New chemical methods for synthesizing polynucleotides; Nuc. Acids Res. Symp. Ser. (1980) 7:215-233.
25.		Crea, et al.; Synthesis of oligonucleotides on cellulose by a phosphotriester method; Nuc. Acids Res. (1980) Vol. 8 No. 10 pp. 2331-2347.
26.		Matteucci, et al.; The synthesis of oligodeoxypyrimidines on a polymer support; Tetrahedron Letters; (1980) Vol. 21, pp 719-722.
27.		Chow, et al.; Synthesis of oligodeoxypyrimidines on Silica gel support; (1981) Vol. 9 No. 12 pp. 2807-2817.
28.		Creighton; Purification of peptides; Proteins structures and molecular principles, W.H. Freeman and Co. NY (1983) pp. 50-60.
29.		Creighton; Purification of peptides; Proteins structures and molecular principles, W.H. Freeman and Co. NY (1983) pp. 34-49.
30.		Logan, et al.; Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection; Proc. Natl. Acad. Sci. (1984) Vol. 81. Pp. 3655-3659.
31.		Mackett, et al.; Vaccinia virus: A selectable eukaryotic cloning and expression vector; Proc. Natl. Acad. Sci. (1982) 79:7415-7419.
32.		Mackett, et al.; General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes; J. of Virology; (1984) 49:857-864.
33.		Panicall, et al.; Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus; Proc. Natl. Acad. Sci. (1982) 79:4927-4931.

34.		Bitter, et al.; Expression and Secretion Vectors for Yeast; Methods in Enzymol. (1987) 516-544.
35.		Wood, et al.; Complementary DNA coding click beetle luciferases can elicit bioluminescence of different colors; Science; Vol. 244 pp. 700-702.
36.		Frackman, et al.; Cloning, organization, and expression of the bioluminescence genes of xenorhabdus luminescens; J. of Bacteriology; (1990) p. 5767-5773.
37.		Szittner, et al.; Nucleotide sequence, expression, and properties of luciferase coded by lux genes from a terrestrial bacterium; J. of Biological Chemistry; (1990) 235:16581-16587.
38.		Xi, et al.; Cloning and Nucleotide sequences of lux genes and characterization of luciferase of xenorhabdus luminescens from a human wound; J. of Bacteriology (1991) 173:1399-1405.
39.		Kovacs, et al.; Firefly luciferase as a marker for herpesvirus (pseudorabies virus) replication in vitro and in vivo; J. of General Virology (1991) 72:2999-3008.
40.		Brasier, et al.; Luciferase reporter gene assay in mammalian cells; Meth. In Enzymol. (1992) 216:386-396.
41.		Israel, et al.; A bioluminescence assay for gene expression by continuously growing mammalian cells: application for detection of human immunodeficiency virus type 1 (HIV-1); Gene (1991) 104:139-145.
42.		Hooper, et al.; CCD Imaging of luciferase gene expression in single mammalian cells; J. of Biolum. And Chemilum (1990) 5:123-130.
43.		Bronstein, et al.; Chemiluminescent reporter gene assays: sensitive detection of the GUS and SEAP gene products; Biotechniques; Biotechniques (1994) 17:172-177.
44.		Bonhoeffer; Optical imaging of intrinsic signals as a tool to visualize the functional architecture of adult and developing visual cortex; Arneimittelforschung (1995) 45:351-356.
45.		Ng, et al.; Optical studies of a bacterial photoreceptor protein, photoactive yellow protein, in single crystals; Biochemistry (1995) 34:879-890.
46.		Vitkin, et al.; Optical and thermal characterization of natural (sepia officinalis) melanin; Photochemistry and Photobiology; 59:455-462.
47.		Chalfie, et al.; Green Fluorescent Protein as a marker for gene expression; Science (1994) 263:802-805.
48.		Daubner, et al.; Yellow light emission of vibrio fischeri strain Y-1: Purification and characterization of the energy-accepting yellow fluorescent protein; Proc. Natl. Acad. Sci.; (1987) 84:8912-8916.
49.		Chance, et al.; Effects of solutes on optical properties of biological materials: Models, cells, and tissues; Analytical Biochemistry (1995) 227:351-362.
50.		Shen, et al.; Production of unmodified human adult hemoglobin in Escherichia coli; Proc. Natl. Acad. Sci. (1993) Vol. 90 pp 8108-8112.
51.		Pieulle, et al.; Biochemical studies of the c-type cytochromes of the sulfate reducer Desulfovibrio africanus; Biochem. Biophys. Acta (1996) 1273:51-61.
52.		Murdock, et al.; Construction of metabolic operons catalyzing the de novo biosynthesis of indigo in escherichia coli; Biotechnology; (1993) Vol. 11 pp 381-386.
53.		Ogata, et al.; A novel peridinin-chlorophyll a protein (PCP) from the marine dinoflagellate alexandrium cohorticula; FEBS Letters (1994) pp. 367-371.
54.		Al-Shibib, et al.; A study of purified pyocyanine produced by pseudomonas aeruginosa: Properties and Grouping; Acta Microbiologica Polonica (1993) Vol. 42:275-280.
55.		Offermanns, et al.; Gα ₁₅ and Gα ₁₆ Couple a wide variety of receptors to phospholipase C*; J. Biol. Chem. (1995) 270:15175-15180.
56.		Conklin, et al.; Carboxyl-terminal mutations of G _q and G ₁₂ that alter the fidelity of receptor activation; Molecular Pharmacology (1996) 50:885-890.

57.		H. Van Der Putten, et al.; Efficient insertion of genes into the mouse germ line via retroviral vectors; Proc. Natl. Acad. Sci. (1985) 82:6148-6152.
58.		Thompson, et al.; Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells; Cell; (1989) 56: 313-321.
59.		Cecilia W. Lo; Transformation by iontophoretic microinjection of DNA; Cell. Biol.; (1983) 3:1803-1814.
60.		Lavitrano, et al.; Sperm cells as vectors for introducing foreign DNA into eggs; Cell; (1989) 57:717-723.
61.		Gordon; Transgenic Animals; Intl. Review of Cytology; (1989) 115:171-129.
62.		Lasko, et al.; Targeted oncogene activation by site-specific recombination in transgenic mice; (1992) Proc. Natl. Acad. Sci. 89:6232-6236.
63.		Gu, et al.; Deletion of a DNA Polymerase β gene segment in T cells using cell type-specific gene targeting; (1994) Science; 265:103-106.
64.		Lam, et al.; A new type of synthetic peptide library for identifying ligand-binding activity; (1991) Nature; 354:82-84.
65.		Houghten, et al.; Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery; (1991) Nature; 354:84-86.
66.		Songyang, et al.; SH2 Domains recognize specific phosphopeptide sequences; (1993) Cell; 72:767-778.
67.		Rouvinen, et al.; Computer-aided drug design; (1988) Acta Pharm. Fennica; 97:159-166.
68.		Ripka; Computers picture the perfect drug; (1988) New Scientist; 118:54-57.
69.		McKinlay; Rational design of antiviral agents; (1989) Annu. Rev. Pharm. Toxicol.; 29:111-122.
70.		Perry, et al.; The use of 3D modelling databases for identifying structure activity relationships; (1989) QSAR: pp. 189-193.
71.		Lewis, et al.; Automated site-directed drug design; (1989) Proc. R. Soc. Lond.; 236:125-140 and 141-162
72.		Askew, et al.; Molecular recognition with convergent functional groups; (1989) J. Am. Chem. Soc. 111:1082-1090.
73.		Janknecht, et al.; Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus; (1991) Proc. Natl. Acad. Sci. 88:8972-8976.
74.		Kohler, et al.; Continuous cultures of fused cells secreting antibody of predefined specificity; (1975) Nature 256:495-497.
75.		Kozbor, et al.; The production of monoclonal antibodies from human lymphocytes; (1983) Immunology Today 4:72- 79.
76.		Cote, et al.; Generation of human monoclonal antibodies reactive with cellular antigens; (1983) Proc. Natl. Acad. Sci. 80:2026-2030.
77.		Cole, et al.; The EBV-hybridoma technique and its application to human lung cancer; (1985) Monoclonal Antibodies and Cancer Therapy pp. 77-96.
78.		Morrison, et al.; Chimeric human antibody molecules; (1984) Proc. Natl. Acad. Sci. 81:6851-6855.
79.		Neuberger, et al.; Recombinant antibodies possessing novel effector functions; (1984) Nature 312:604-608.
80.		Takeda, et al.; Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences; (1985) Nature 314:452-454.
81.		Bird, et al.; Single-chain antigen-binding proteins; (1988) Science 242:423-426.
82.		Ward, et al.; Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli; (1989) Nature 334:544-546.
83.		Huse, et al.; Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda; (1989) Science 246:1275-1281.

84.		Greenspan, et al.; Idiotypes: structure and immunogenicity; (1993) FESEB J. 7:437-444.
85.		Nisonoff; Idiotypes: concepts and applications; (1991) J. Immunol. 147:2429-2438.
86.		Wagner; Gene inhibition using antisense oligodeoxynucleotides; (1994) Nature 372:333-335.
87.		Sarver, et al.; Ribozymes as potential anti-HIV-1 therapeutic agents; (1990) Science; 247:1222-1225.
88.		Haseloff, et al.; Simple RNA enzymes with new and highly specific endoribonuclease activities; (1988) Nature 334:585-591.
89.		Zaug, et al.; A labile phosphodiester bond at the ligation junction in a circular intervening sequence RNA; (1984) Science 224:574-578.
90.		Zaug, et al.; The intervening sequence RNA of tetrahymena is an enzyme; (1986) Science 231:470-475.
91.		Zaug, et al.; The tetrahymena ribozyme acts like an RNA restriction endonuclease; (1986) Nature 324:429-433.
92.		Been, et al.; One binding site determines sequence specificity of tetrahymena Pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity; (1986) Cell 47:207-216.
93.		Smithies, et al.; Insertion of DNA sequences into the human chromosomal β -globin locus by homologous recombination; (1985) Nature 317:230-234.
94.		Thomas, et al.; Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells; (1987) Cell 51:503-512.
95.		Helene; The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides; (1991) Anti-cancer drug design 6:569-584.
96.		Helene; Control of gene expression by triple helix-forming oligonucleotides; (1992) Ann NY Acad. Sci. 660:27-36.
97.		Maher; DNA triple-helix formation: An approach to artificial gene repressors; (1992) Bioassays 14:807-815.
98.		Cubitt, et al.; Understanding, Improving and using green fluorescent proteins; (1995) TIBS 20:448-455.
99.		Huston, et al.; Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in escherichia coli; (1988) Proc. Natl. Acad. Sci. 85:5879-5883.
EXAMINER		DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		